Amgen Inc.
PAC1 ANTIBODIES AND USES THEREOF
Last updated:
Abstract:
The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
Status:
Application
Type:
Utility
Filling date:
1 Jul 2020
Issue date:
21 Jan 2021